NRX

NurExone Launches Licensing Efforts for ExoTherapy Platform

Retrieved on: 
Wednesday, February 14, 2024
EVS, Messenger, Plasma protein binding, Exosome, NRX, PCT, Cell, Seminal vesicles, RNA, Patent, Patient, Listeria monocytogenes non-coding RNA, MicroRNA, Carbohydrate, Small RNA, Tissue, Environment, Fine chemical

TORONTO and HAIFA, Israel, Feb. 14, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company, announced today the commencement of efforts to license its proprietary ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.

Key Points: 
  • TORONTO and HAIFA, Israel, Feb. 14, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company, announced today the commencement of efforts to license its proprietary ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.
  • The Company’s ExoTherapy platform for exosome-based therapy production includes: (i) large-scale exosome production using the Company’s dedicated bioreactor, (ii) synthesis of therapeutic cargo and (iii) processes to load the therapeutic cargo, creating nanodrugs.
  • Dr. Lior Shaltiel, CEO of NurExone, commented, “Exosomes have the potential to be the ultimate drug delivery system.
  • ExoPTEN, for patients with acute spinal cord injuries, is being developed on our platform, and we expect great success through licensing our technology for other indications!”.

Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant

Retrieved on: 
Friday, February 2, 2024
NRX, CMC, European, Orphan drug, Patient, FDA, EMA, Orphan, Food, European Medicines Agency, Pharmaceutical industry

This strategic move follows the recent grant of Orphan Drug Designation by the U.S. Food and Drug Administration (“FDA”) for ExoPTEN.

Key Points: 
  • This strategic move follows the recent grant of Orphan Drug Designation by the U.S. Food and Drug Administration (“FDA”) for ExoPTEN.
  • Dr. Ina Sarel, Head of CMC, Quality, and Regulation at NurExone Biologic, expressed enthusiasm about the development, stating, "Embarking on the European Orphan Drug Designation process marks a crucial milestone in our mission to bring life-changing treatments to patients in need around the world."
  • The initiation of the European Orphan Drug Designation process represents a strategic move to broaden the reach of this promising treatment globally.
  • To expedite the application process, the Company has enlisted the expertise of an external consultant to secure European Orphan Drug Designation.

NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market

Retrieved on: 
Wednesday, January 17, 2024
Spinal cord injury, Agreement, Patient, Advertising, Exosome, Administration, NRX, SCI, TSX Venture Exchange, Pharmaceutical industry

The collaborative agreement between NurExone and Inteligex Inc. (“Inteligex”), announced in October 2023, to expand the Company’s portfolio, is now officially underway.

Key Points: 
  • The collaborative agreement between NurExone and Inteligex Inc. (“Inteligex”), announced in October 2023, to expand the Company’s portfolio, is now officially underway.
  • As part of this collaboration, we will use our platform to produce and load exosomes from Inteligex’s cell line to deliver combination regenerative therapy for Spinal Cord Injury (SCI) patients.
  • This win-win collaboration will expand our potential markets and is in line with our belief of patient, first.”
    Dr. Paul Bradshaw, CEO of Inteligex, stated that “Spinal cord injury is the single most expensive healthcare condition in the world.
  • The Agreement is effective for four months from the effective date and the total consideration payable to BullVestor is CAD$300,000 on the effective date.

NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million

Retrieved on: 
Friday, January 5, 2024
Regulation, Placement, Private, TSX Venture Exchange, CFO, Indian stock exchange, Person, CAD, News, Unit, NRX, Patient, Security (finance)

An aggregate of 7,091,993 units of the Company (each a “Unit”) were issued and sold under the Private Placement at a price of CAD$0.28 per Unit for aggregate proceeds of CAD$1,985,758.04.

Key Points: 
  • An aggregate of 7,091,993 units of the Company (each a “Unit”) were issued and sold under the Private Placement at a price of CAD$0.28 per Unit for aggregate proceeds of CAD$1,985,758.04.
  • Each Warrant entitles the holder thereof to purchase one Common Share at a price of CAD$0.35 per Common Share for a period of 36 months from the closing of the Private Placement.
  • All securities issued under the Private Placement are subject to a statutory hold period of four months and one day from the closing of the Private Placement.
  • The Company intends to use the proceeds of the Private Placement for working capital purposes.

NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration

Retrieved on: 
Wednesday, November 29, 2023
RNA, Protein, Regeneration, Small RNA, Spinal cord, Human, Exosome, Tetraplegia, Fig, Patent, CNS, NRX, PNN, Neuron, Vaccine

The biopharmaceutical company is using its biologically-guided exosome therapy ExoTherapy platform to expand its portfolio of products that will address spinal cord injuries and regeneration of neurons in other CNS indications.

Key Points: 
  • The biopharmaceutical company is using its biologically-guided exosome therapy ExoTherapy platform to expand its portfolio of products that will address spinal cord injuries and regeneration of neurons in other CNS indications.
  • In the latest development, NurExone has developed two selective small inhibiting RNA sequences (siRNA) that target and inhibit proteins within the Peri-Neural Network (PNN) complex (Fig.
  • The breakthrough sequences, detailed in a patent application held by the Company, are built upon a scientifically validated strategy for enhanced neuronal regeneration via inhibition of the PNN complex.
  • The Company believes that its innovative approach, using the Company’s ExoTherapy platform to deliver these RNA sequences, will overcome limitations of previous methods.

NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, November 24, 2023
Private, Neurosurgery, IND, Drug development, Drug discovery, Indian stock exchange, Research, Small RNA, CAD, Spinal cord, Patent, Health, Exosome, Investigational New Drug, Advisory Committee, PTEN, Unit, Option, NRX, Therapy, Food and Drug Administration, Exercise, Pharmaceutical industry

TORONTO and HAIFA, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a pioneering biotechnology company, released a corporate update and reported financial results for the quarter ended September 30, 2023.

Key Points: 
  • TORONTO and HAIFA, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a pioneering biotechnology company, released a corporate update and reported financial results for the quarter ended September 30, 2023.
  • Research and development expenses were US$0.40 million in the third quarter of 2023, compared to US$0.42 million in the same quarter in 2022.
  • Financial (income) expenses were (US$0.01) million in the third quarter of 2023, compared to US$0.02 million in the same period in 2022.
  • Net loss was US$1.16 million in the third quarter of 2023, compared to a net loss of US$1.04 million in the same quarter in 2022.

NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment

Retrieved on: 
Monday, October 30, 2023
FDA, PTEN, Food, Rare, RNA, NRX, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Drug development, ODD, MSC, FSE, EVS, Patient, Small RNA, Pharmaceutical industry

The orphan drug designation provides significant benefits to pharmaceutical companies developing drugs for rare diseases, i.e.

Key Points: 
  • The orphan drug designation provides significant benefits to pharmaceutical companies developing drugs for rare diseases, i.e.
  • These benefits include market exclusivity, financial incentives, regulatory assistance, and support with drug development.
  • Overall, the designation incentivizes and supports the development of certain treatments, increasing access to therapies for patients.
  • We appreciate the formal recognition of the potential impact of our therapy on the lives of patients suffering from acute spinal cord injuries,” said Dr. Shaltiel, CEO of NurExone Biologic, Ltd.

Appointment of Professor Teo Forcht Dagi to Scientific Advisory Board and Advisory Committee

Retrieved on: 
Thursday, October 19, 2023
Mayo Clinic Alix School of Medicine, Exosome, NRX, Coronavirus Scientific Advisory Board, Growth, Medicine, DSM-IV codes, Advisory Committee, FSE, Patient, Pharmaceutical industry

Professor Dagi’s decision to join the Scientific Advisory Board stems from his profound belief in the regenerative potential of exosomes for neurological diseases.

Key Points: 
  • Professor Dagi’s decision to join the Scientific Advisory Board stems from his profound belief in the regenerative potential of exosomes for neurological diseases.
  • According to Professor Dagi, “The problem of neural regeneration and recovery from neurological injury is one of the most difficult and pressing unresolved problems in medicine.
  • Our heartfelt condolences go out to families with lost or missing loved ones.
  • We extend sincere appreciation to our investors and partners for their continued warm support.

NurExone Secures Eureka Grant for Collaborative Partnership to Expand to Chronic Spinal Cord Injury Therapy

Retrieved on: 
Wednesday, October 11, 2023
Partnership, Israel Innovation Authority, Cell damage, SCI, Spinal cord, Diffuse axonal injury, Paralysis, Research, Medicine, Inflammation, Cell death, NRX, Patient, IIA, Exosome, NIS, FSE, Pharmaceutical industry, Medical device

The grant is for a collaboration with Canada-based Inteligex Inc. (“Inteligex”) to develop an innovative hybrid therapy tailored for the complex chronic spinal cord injury market.

Key Points: 
  • The grant is for a collaboration with Canada-based Inteligex Inc. (“Inteligex”) to develop an innovative hybrid therapy tailored for the complex chronic spinal cord injury market.
  • Currently, NurExone is in the process of developing the ExoPTEN product specifically for acute spinal cord injuries.
  • This collaborative effort opens the possibility for the Company to expand its focus to chronic spine injuries.
  • Dr. Lior Shaltiel, CEO of NurExone, expressed his excitement about this prestigious grant, stating, “NurExone aims to lead in functional recovery for both acute and chronic segments of the multi-billion-dollar spinal cord injury market.

NurExone Biologic to Present Exosome-Based Therapy for Spinal Cord Injury in Regenerative Medicine Session at Upcoming Extracellular Vesicles Forum

Retrieved on: 
Thursday, October 5, 2023
Food, SCI, 3D, Seminal vesicles, EVS, PTEN, NRX, FSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Small RNA, CNS, Patient, Exosome, Pharmaceutical industry

Dr. Shaltiel’s presentation will focus on the transformative potential of extracellular vesicles loaded with PTEN-siRNA (ExoPTEN) and the key challenges in translating this innovative therapy to the clinical stage, following the positive response from the Company’s pre-IND meeting with the U.S. Food and Drug Administration that was announced recently.

Key Points: 
  • Dr. Shaltiel’s presentation will focus on the transformative potential of extracellular vesicles loaded with PTEN-siRNA (ExoPTEN) and the key challenges in translating this innovative therapy to the clinical stage, following the positive response from the Company’s pre-IND meeting with the U.S. Food and Drug Administration that was announced recently.
  • During the presentation, Dr. Shaltiel will address critical aspects of NurExone’s ExoTherapy (exosome-based therapy), including the loading efficiency of extracellular vesicles (EVs) with siRNA and the large-scale production of EVs utilizing a revolutionary 3D bioprocess concept.
  • These advancements represent a step forward in the field of recovery from spinal cord injury and hold promise for patients globally.
  • The presentation will take place at the Extracellular Vesicles Forum in Cambridge, UK, on October 10th and 11th at the session titled “Exosome Based Therapies and Regenerative Medicine.” Dr. Shaltiel will be available for one-on-one meetings during the conference.